Pfizer begins phase I study of COVID-19 drug targeting main protease

By The Science Advisory Board staff writers

September 16, 2020 -- Pfizer has begun a phase Ib clinical trial to evaluate the safety of an investigational COVID-19 drug candidate, PF-00835321, that blocks the main protease SARS-CoV-2 enzyme.

The study is a double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of the candidate.

In preliminary preclinical studies conducted by New York University (NYU) Grossman School of Medicine and Pfizer, the drug was shown to block the action of the main protease, which is necessary for the replication of SARS-CoV-2. In one set of cell culture experiments, the candidate was found to be 3.3 times more potent a blocker of replication compared to remdesivir, the only antiviral drug authorized for emergency use against COVID-19.

A study posted to bioRxiv evaluating the candidate in 3D airway model cells demonstrated that it is effective at lower concentrations than other drugs targeting the main protease that are currently under development.

Pfizer designed, manufactured, and supplied PF-00835231 for the preclinical experiments. NYU Langone researchers performed the study experiments, building on their extensive research with influenza to design one of the first airway cell culture model systems for the study of SARS-CoV-2.

Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government...
Pfizer to manufacture remdesivir for Gilead
Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other...
Pfizer, BioNTech get $1.95B for SARS-CoV-2 vaccine
Pfizer and BioNtech have inked an agreement with the U.S. Department of Health and Human Services and the Department of Defense, as part of the federal...
Sorrento plans phase II trial for COVID-19 treatment
Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment...
Pfizer, BioNTech give details about mRNA COVID-19 vaccine deal
Biopharmaceutical New Technologies (BioNTech) and Pfizer have released additional details regarding their collaboration to advance the mRNA COVID-19 vaccine...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter